Jeffrey Dover is a Dermatology physician. OpenAlex indexes 546 publications with 12,847 citations (h-index 59); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Dermatology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1244 Boylston St
Suite 302
Chestnut Hill, MA 024672116
Telephone
617-731-1600Registry record last updated 8 Jul 2007.
Clinical trials
- Evaluation of the Evoke Radiofrequency Device for Improvement of Skin Appearance
Sponsor: InMode MD Ltd.
- Pilot Study of Multi-wavelength Laser for Tattoo Removal
Sponsor: Cutera Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Solta Medical, a division of Bausch Health US, LLCProgram year20253 payments$24,655openpaymentsdata.cms.gov ↗
- REVANCE THERAPEUTICS, INC.Program year20252 payments
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
44.8%Azole Antifungal19.7%Ketoconazole100%Part D≥21 patientsTetracycline-class Drug10.9%Doxycycline Hyclate54%Seysara46%Part D<11 patients+ 2 more classes in this area
Dermatology
33.5%Corticosteroid27.6%Triamcinolone acetonide55%Triamcinolone Acetonide46%Part D + Part B≥19 patientsInterleukin-4 Receptor alpha Antagonist5.9%Dupixent Pen100%Part D<11 patientsSensory organs
17.2%Corticosteroid17.2%Clobetasol Propionate73%Betamethasone Dipropionate27%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”